BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33528002)

  • 1. Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure.
    Robson JC; Almeida C; Dawson J; Bromhead A; Dures E; Guly C; Hoon E; Mackie S; Ndosi M; Pauling J; Hill C
    Rheumatology (Oxford); 2021 Oct; 60(10):4671-4680. PubMed ID: 33528002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure.
    Bridgewater S; Shepherd MA; Dawson J; Richards P; Silverthorne C; Ndosi M; Almeida C; Black RJ; Cheah JTL; Dures E; Ghosh N; Hoon EA; Lyne S; Navarro-Millan I; Pearce-Fisher D; Ruediger C; Tieu J; Yip K; Mackie SL; Goodman S; Hill C; Robson JC
    Rheumatology (Oxford); 2023 Nov; 62(11):3565-3575. PubMed ID: 36840642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a patient-reported outcome measure for giant cell arteritis.
    Ndosi M; Almeida C; Dawson J; Dures E; Greenwood R; Bromhead A; Guly C; Stern S; Hill C; Mackie S; Robson JC
    Rheumatology (Oxford); 2024 Jan; 63(1):181-189. PubMed ID: 37144946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the impact of giant cell arteritis on patients' lives? A UK qualitative study.
    Liddle J; Bartlam R; Mallen CD; Mackie SL; Prior JA; Helliwell T; Richardson JC
    BMJ Open; 2017 Aug; 7(8):e017073. PubMed ID: 28838902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.
    Sreih AG; Alibaz-Oner F; Kermani TA; Aydin SZ; Cronholm PF; Davis T; Easley E; Gul A; Mahr A; McAlear CA; Milman N; Robson JC; Tomasson G; Direskeneli H; Merkel PA
    J Rheumatol; 2017 Dec; 44(12):1933-1937. PubMed ID: 28864646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
    Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
    RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Giant Cell Arteritis.
    Guevara M; Kollipara CS
    Curr Rheumatol Rep; 2018 Apr; 20(5):25. PubMed ID: 29611005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond the symptoms: Personalizing giant cell arteritis care through multidimensional patient reported outcome measure.
    El Miedany Y; El Gaafary M; Toth M; Palmer D; Ali A; Bahlas S; Mahran S; Hassan W; Abu-Zaid MH; Saber S; Elwakil W
    Semin Arthritis Rheum; 2023 Dec; 63():152285. PubMed ID: 37944298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of outcome measures for giant cell arteritis for use in clinical trials and standard practice.
    El Miedany Y; Elgaafary M; Toth M; Azim AA; Palmer D; Dolbear G; Abu-Zaid MH; Affam D; Hassan W; Elnady B; Tabra SA; Saber S
    Clin Rheumatol; 2023 Nov; 42(11):3049-3057. PubMed ID: 37464103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
    Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
    Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report.
    Cho YM; El Khoury L; Paramo J; Horowitz DM; Li JY; Kello N
    BMC Musculoskelet Disord; 2023 May; 24(1):382. PubMed ID: 37189114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative Data.
    Austin K; Dures E; Almeida C; Cramp F; Guly CM; Hill CL; Hoon EA; Mackie S; O'Brien AV; Watts RA; Robson JC
    Arthritis Care Res (Hoboken); 2022 Jan; 74(1):99-106. PubMed ID: 34590437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure.
    Robson JC; Dawson J; Cronholm PF; Milman N; Kellom KS; Ashdown S; Easley E; Farrar JT; Gebhart D; Lanier G; McAlear CA; Peck J; Luqmani RA; Shea JA; Tomasson G; Merkel PA
    Patient Relat Outcome Meas; 2018; 9():17-34. PubMed ID: 29379322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Headache Federation recommendations for neurologists managing giant cell arteritis.
    Mollan SP; Paemeleire K; Versijpt J; Luqmani R; Sinclair AJ
    J Headache Pain; 2020 Mar; 21(1):28. PubMed ID: 32183689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of giant cell arteritis.
    González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
    Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.